Sanofi, Denali Enter Collaboration Deal Valued at Up to $1 Billion
01 November 2018 - 5:52PM
Dow Jones News
By Donato Paolo Mancini
Sanofi SA (SAN.FR) and Denali Therapeutics Inc. (DNLI) have
entered a collaboration agreement valued at up to $1.02 billion to
develop molecules to treat neurological and systemic inflammatory
diseases, the two companies said Thursday.
Under the terms of the deal Sanofi will make an upfront cash
payment of $125 million to Denali, the companies said. The
remaining $895 million is for clinical and regulatory milestone
payments, a Sanofi spokeswoman said.
The two lead molecules, DNL747 and DNL758, target a signaling
protein that regulates inflammation and cell death in tissues
throughout the body, the two companies said.
The companies plan on studying DNL747 in Alzheimer's disease,
amyotrophic lateral sclerosis (ALS)and multiple sclerosis (MS).
DNL758 will be studied in systemic inflammatory diseases like
rheumatoid arthritis and psoriasis.
The transaction is expected to close in the coming months,
pending regulatory approval.
Write to Donato Paolo Mancini at
donatopaolo.mancini@dowjones.com
(END) Dow Jones Newswires
November 01, 2018 02:37 ET (06:37 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Sep 2024 to Oct 2024
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Oct 2023 to Oct 2024